Victoria P. Werth, M.D.
Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center
Division Of Dermatology, University of Pennsylvania Health System (to include the Hospital of the University of Pennsylvania and Presbyterian Hospital)
Department: Dermatology
Contact information
Division of Dermatology
Veterans Administration Hospital
University and Woodland Avenues
Philadelphia, PA 19104
Veterans Administration Hospital
University and Woodland Avenues
Philadelphia, PA 19104
Office: 215-823-4208
Fax: 215-823-5171
Fax: 215-823-5171
Links
International Pemphigus and Pemphigoid Foundation
Medical Dermatology Society
Philadelphia Dermatology Society
The Myositis Association
Lupus Research Institute
Lupus Foundation of America
Pennsylvania Academy of Dermatology
Scleroderma Foundation
International Pemphigus and Pemphigoid Foundation
Medical Dermatology Society
Philadelphia Dermatology Society
The Myositis Association
Lupus Research Institute
Lupus Foundation of America
Pennsylvania Academy of Dermatology
Scleroderma Foundation
Education:
BA (Chemistry)
Catholic University, 1976.
MS (Physical Chemistry)
Catholic University, 1976.
M.D. (Medicine)
Johns Hopkins University, 1980.
Permanent linkBA (Chemistry)
Catholic University, 1976.
MS (Physical Chemistry)
Catholic University, 1976.
M.D. (Medicine)
Johns Hopkins University, 1980.
Description of Research Expertise
PhotobiologyTumor necrosis factor
Cutaneous lupus
Glycosaminoglycans
Clinical and translational research in cutaneous autoimmune diseases
Description of Clinical Expertise
Autoimmune skin diseaseCutaneous Lupus Erythematosus
Dermatomyositis
Pemphigus vulgaris
Selected Publications
Kleitsch, J., Weiner, J.D., Pandya, R. et al: The physical and emotional impact of cutaneous dermatomyositis: a qualitative study. Arch Dermatol Res 315(8): 2431-2435, October 2023.Dan J, Sprow G, Concha J, Patel J, Kodali N, Diaz D, Vazquez T, Werth VP.: A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis. Br J Dermatol 189(2): 227-228, July 2023.
Desai AD, Werth VP, Elman SA.: Characterizing primary hospitalizations for systemic lupus erythematosus in the United States. Rheumatology (Oxford) 12: 290, June 2023.
Pandya R, Dan J, Kleitsch J, White B, Werth VP.: Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial. J Invest Dermatol(23), Jun 2023.
Dan J, Sprow G, Concha J, Patel J, Kodali N, Diaz D, Vazquez T, Werth VP: A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis Br J Dermatol 189(2): 227-228, May 2023.
Yale M, Dunn P, Strong R, Davies I, Gallu L, Joly P, Murrell DF, Werth VP, Payne AS: The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid J Invest Dermatol S0022-202X(23): 01971-1, May 2023.
Cordel N, Dechelotte B, Jouen F, Lamb JA, Chinoy H, New P, Vencovsky J, Mann H, Galindo-Feria AS, Dani L, Selva-O'Callaghan A, Werth VP, Ravishankar A, Landon-Cardinal O, Tressières B, Boyer O: Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology (Oxford) 62(4): 1711-1715, April 2023.
Pandya R, Kleitsch J, Werth VP: Trial of intravenous immune globulin in dermatomyositis: a critically appraised research paper. Br J Dermatol 188(6): 738-739, March 2023.
García-Romero MT, Tollefson M, Pope E, Brandling-Bennett HA, Paller AS, Keimig E, Arkin L, Wanat KA, Humphrey SR, Werth VP, Oza V, Jacobe H, Fett N, Cordoro KM, Medina-Vera I, Chiu YE: Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea. JAMA Dermatol 159(3): 299-307, March 2023.
Morand E, Pike M, Merrill JT, Van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Shah V, Sharkey B, Wegman T, Ctlett I, Banerjee S, Singhal S: Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus rythematosus: a phase 2, randomized, double-blind, placebo-controlled study Arthritis Rheumatol 75(2): 242-252, February 2023.